» Articles » PMID: 27843941

Transitional Remodeling of the Hepatic Extracellular Matrix in Alcohol-Induced Liver Injury

Overview
Journal Biomed Res Int
Publisher Wiley
Date 2016 Nov 16
PMID 27843941
Citations 19
Authors
Affiliations
Soon will be listed here.
Abstract

Alcohol consumption is a common custom worldwide, and the toxic effects of alcohol on several target organs are well understood. The liver is the primary site of alcohol metabolism and is therefore the major target of alcohol toxicity. Alcoholic liver disease is a spectrum of disease states, ranging from simple steatosis (fat accumulation), to inflammation, and eventually to fibrosis and cirrhosis if untreated. The fibrotic stage of ALD is primarily characterized by robust accumulation of extracellular matrix (ECM) proteins (collagens) which ultimately impairs the function of the organ. The role of the ECM in early stages of ALD is poorly understood, but recent research has demonstrated that a number of changes in the hepatic ECM in prefibrotic ALD not only are present, but may also contribute to disease progression. The purpose of this review is to summarize the established and proposed changes to the hepatic extracellular matrix (ECM) that may contribute to earlier stages of ALD development and to discuss potential mechanisms by which these changes may mediate the progression of the disease.

Citing Articles

Bioengineering scalable and drug-responsive in vitro human multicellular non-alcoholic fatty liver disease microtissues encapsulated in the liver extracellular matrix-derived hydrogel.

Asadollahi N, Hajari M, Alipour Choshali M, Ajoudanian M, Ziai S, Vosough M EXCLI J. 2024; 23:421-440.

PMID: 38741724 PMC: 11089098. DOI: 10.17179/excli2023-6878.


The plasma degradome reflects later development of NASH fibrosis after liver transplant.

Li J, Sato T, Hernandez-Tejero M, Beier J, Sayed K, Benos P Sci Rep. 2023; 13(1):9965.

PMID: 37340062 PMC: 10282030. DOI: 10.1038/s41598-023-36867-x.


Bioengineering liver microtissues for modeling non-alcoholic fatty liver disease.

Aasadollahei N, Rezaei N, Golroo R, Agarwal T, Vosough M, Piryaei A EXCLI J. 2023; 22:367-391.

PMID: 37223084 PMC: 10201011. DOI: 10.17179/excli2022-5892.


Effect of alcohol exposure on the efficacy and safety of tenofovir alafenamide fumarate, a major medicine against human immunodeficiency virus.

Liu W, Yu S, Yan B Biochem Pharmacol. 2022; 204:115224.

PMID: 36007574 PMC: 10225116. DOI: 10.1016/j.bcp.2022.115224.


Alcohol-Associated Tissue Injury: Current Views on Pathophysiological Mechanisms.

Simon L, Souza-Smith F, Molina P Annu Rev Physiol. 2022; 84:87-112.

PMID: 35143331 PMC: 11268381. DOI: 10.1146/annurev-physiol-060821-014008.


References
1.
Gillis S, Nagy L . Deposition of cellular fibronectin increases before stellate cell activation in rat liver during ethanol feeding. Alcohol Clin Exp Res. 1997; 21(5):857-61. View

2.
Lazaro R, Wu R, Lee S, Zhu N, Chen C, French S . Osteopontin deficiency does not prevent but promotes alcoholic neutrophilic hepatitis in mice. Hepatology. 2014; 61(1):129-40. PMC: 4280361. DOI: 10.1002/hep.27383. View

3.
Ganey P, Luyendyk J, Maddox J, Roth R . Adverse hepatic drug reactions: inflammatory episodes as consequence and contributor. Chem Biol Interact. 2004; 150(1):35-51. DOI: 10.1016/j.cbi.2004.09.002. View

4.
Naba A, Clauser K, Ding H, Whittaker C, Carr S, Hynes R . The extracellular matrix: Tools and insights for the "omics" era. Matrix Biol. 2015; 49:10-24. PMC: 5013529. DOI: 10.1016/j.matbio.2015.06.003. View

5.
Beier J, Arteel G, McClain C . Advances in alcoholic liver disease. Curr Gastroenterol Rep. 2010; 13(1):56-64. PMC: 3772541. DOI: 10.1007/s11894-010-0157-5. View